Home » Company » Optibiotix Health PLC
Optibiotix Health Plc

Optibiotix Health PLC

  • Profile
  • News
  • Interviews
  • Data

OptiBiotix Health PLC (LON:OPTI) exploit recent scientific advances to develop a range of products which can modify the human microbiome and bring specific health benefits. This will meet a large and growing consumer need for nutritional and effective health care products supported by scientific evidence and clinical studies. With increasing scientific corroboration of health benefits from products which modify the human microbiome this sector has been predicted to become one of the world’s fastest growth areas in the next 10 years.

MicrobiomeThe prospect of modulating the human microbiome to prevent, manage, and treat human disease has led the human microbiome to be described as one of the most significant scientific breakthroughs of 2013 and one of the top 10 emerging technologies of 2014.

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations which modulate the human microbiome and can be used as food ingredients, supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary

OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

OptiBiotix has developed a portfolio of intellectual property in and around this field of research, consisting of patents, trademarks and novel microbial strains. Further intellectual property is expected to be developed or acquired as opportunities arise from existing and future research and development.

OptiBiotix has been working with leading international key opinion leaders and entered into a research agreement with the University of Reading on 18 September 2012 to generate novel microbiome modulating compounds using reverse enzyme synthesis. All intellectual property arising from this research is owned by OptiBiotix.

 

Optibiotix Health PLC Board Members

Chairman: David Evans
Chief Executive: Stephen OHara
Non Executive Directors: Dr Mark Wyatt and Adam Reynolds

Company website for Optibiotix Health PLC

http://www.optibiotix.com/